Unanswered questions following reports of secondary malignancies after CAR-T cell therapy

Levine, B. L.; Pasquini, M. C.; Connolly, J. E.; Porter, D. L.; Gustafson, M. P.; Boelens, J. J.; Horwitz, E. M.; Grupp, S. A.; Maus, M. V.; Locke, F. L.; Ciceri, F.; Ruggeri, A.; Snowden, J.; Heslop, H. E.; Mackall, C. L.; June, C. H.; Sureda, A. M.; Perales, M. -A.

doi:10.1038/s41591-023-02767-w

Reports of T cell malignancies after CAR-T cell therapy should be investigated, but existing data from follow-up studies suggest a low risk compared with other cancer treatments.

Unanswered questions following reports of secondary malignancies after CAR-T cell therapy / Levine, B.L., Pasquini, M.C., Connolly, J.E., Porter, D.L., Gustafson, M.P., Boelens, J.J., Horwitz, E.M., Grupp, S.A., Maus, M.V., Locke, F.L., Ciceri, F., Ruggeri, A., Snowden, J., Heslop, H.E., Mackall, C.L., June, C.H., Sureda, A.M., Perales, M.-A.. - In: NATURE MEDICINE. - ISSN 1078-8956. - 30:2(2024), pp. 338-341. [10.1038/s41591-023-02767-w]